Don't miss it: New episode of Off-Target Effects with Matt Gline and guest Phil Ross of Jefferies dropping tomorrow on BiotechTV. Watch the teaser below ⬇️⬇️⬇️

Episode #4 of Off-Target Effects is out! Our CEO and show host Matt Gline interviews Philip Ross from @jefferies to talk about the @blueprintmeds deal with Sanofi, the future of M&A, and Philip’s recent career move. Find it all below on @biotechtv

Tune into Roivant Q1 earnings happening Monday AM - details below investor.roivant.com/news-releases/…

We’re thrilled to be recognized as a 2025 Best Workplace in BioPharma™. This recognition demonstrates Roivant’s commitment to building a high-performance and talent-oriented culture. Learn about this achievement: bit.ly/3VL2MeM #BestWorkplaces #GPTWCertified

This morning, Roivant and Priovant announced positive Phase 3 VALOR study results for brepocitinib in dermatomyositis - find the press release with more details here investor.roivant.com/news-releases/…

#NEWS: Along with Priovant Therapeutics, we announced positive results from the Phase 3 VALOR study evaluating our inflammatory disease prospect in dermatomyositis (DM). Learn more about this exciting moment for the DM community: bit.ly/3K7WLX5

Graves' Disease causes an overactive thyroid and hyperthyroidism, with symptoms like nervousness, anxiety, and more. See how we strive to meet the complex and variable needs of people with Graves’ disease through our latest research: bit.ly/4gCH9qJ #GravesDisease

Graves’ disease, an autoimmune disease, disproportionately impacts women. Learn how Immunovant is applying a patient-focused approach to help advance treatment for people living with this condition: bit.ly/47gO44x #GravesDisease

We were honored with the Double Helix Award at Life Science Cares’ Impact Night! Thank you Life Science Cares New York for helping us be on the frontlines making a difference for patients and communities in need.

Today, we reported our Q2 financial results. Find key highlights here: bit.ly/4p5Jr4M